BioCryst Pharma (BCRX) Tops Q1 EPS by 7c ; Offers Guidance

BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of $0.00, $0.07 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $134.2 million versus the consensus estimate of $127.91 million.

GUIDANCE:

BioCryst Pharma sees FY2025 revenue of $580-600 million, versus the consensus of $563.6 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• UBS Upgrades Smoore International Holdings Limited (6969:HK) (SMORF) to Buy
• Canaccord Upgrades ARB Corp Ltd (ARB:AU) to Buy
• National Bank Financial Downgrades Nutrien (NTR) to Sector Perform